SG11202105718TA - Modified antibodies - Google Patents

Modified antibodies

Info

Publication number
SG11202105718TA
SG11202105718TA SG11202105718TA SG11202105718TA SG11202105718TA SG 11202105718T A SG11202105718T A SG 11202105718TA SG 11202105718T A SG11202105718T A SG 11202105718TA SG 11202105718T A SG11202105718T A SG 11202105718TA SG 11202105718T A SG11202105718T A SG 11202105718TA
Authority
SG
Singapore
Prior art keywords
modified antibodies
antibodies
modified
Prior art date
Application number
SG11202105718TA
Inventor
Simon John Davis
Original Assignee
Univ Oxford Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Oxford Innovation Ltd filed Critical Univ Oxford Innovation Ltd
Publication of SG11202105718TA publication Critical patent/SG11202105718TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
SG11202105718TA 2018-12-17 2019-12-17 Modified antibodies SG11202105718TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1820547.6A GB201820547D0 (en) 2018-12-17 2018-12-17 Modified antibodies
PCT/GB2019/053570 WO2020128447A1 (en) 2018-12-17 2019-12-17 Modified antibodies

Publications (1)

Publication Number Publication Date
SG11202105718TA true SG11202105718TA (en) 2021-07-29

Family

ID=65147105

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202105718TA SG11202105718TA (en) 2018-12-17 2019-12-17 Modified antibodies

Country Status (9)

Country Link
US (1) US20220064300A1 (en)
EP (1) EP3898678A1 (en)
JP (1) JP2022513930A (en)
CN (1) CN113454118A (en)
AU (1) AU2019403984A1 (en)
CA (1) CA3121232A1 (en)
GB (1) GB201820547D0 (en)
SG (1) SG11202105718TA (en)
WO (1) WO2020128447A1 (en)

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JPH11510170A (en) 1995-07-27 1999-09-07 ジェネンテック インコーポレーテッド Protein Formula
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
ATE531812T1 (en) 1997-12-05 2011-11-15 Scripps Research Inst HUMANIZATION OF RODENT ANTIBODIES
GB9818110D0 (en) 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JP3523245B1 (en) 2000-11-30 2004-04-26 メダレックス，インコーポレーテッド Transgenic chromosome-introduced rodents for the production of human antibodies
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
FI2206517T3 (en) 2002-07-03 2023-10-19 Ono Pharmaceutical Co Immunopotentiating compositions comprising anti-PD-L1 antibodies
JP4511943B2 (en) 2002-12-23 2010-07-28 ワイス エルエルシー Antibody against PD-1 and use thereof
US7754209B2 (en) * 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
NZ545968A (en) * 2003-09-18 2010-01-29 Raven Biotechnologies Inc KID3 and KID3 antibodies that bind thereto
LT2439273T (en) 2005-05-09 2019-05-10 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
WO2010029434A1 (en) 2008-09-12 2010-03-18 Isis Innovation Limited Pd-1 specific antibodies and uses thereof
UY33827A (en) * 2010-12-22 2012-07-31 Abbott Lab MEDIUM-IMMUNOGLOBULIN UNION PROTEINS AND ITS USES
EP2776061B1 (en) * 2011-11-07 2019-08-14 MedImmune, LLC Multispecific and multivalent binding proteins and uses thereof
US11059898B2 (en) * 2014-03-24 2021-07-13 Cancer Research Technology Limited Modified antibodies containing modified IGG2 domains which elicit agonist or antagonistic properties and use thereof
CA2948165A1 (en) * 2014-05-08 2015-11-12 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Using b-cell-targeting antigen igg fusion as tolerogenic protein therapy for treating adverse immune responses
IL292508B2 (en) * 2014-12-24 2023-08-01 Autolus Ltd Cell co-expressing cd19 and cd22 chimeric antigen receptor (car)

Also Published As

Publication number Publication date
CN113454118A (en) 2021-09-28
GB201820547D0 (en) 2019-01-30
US20220064300A1 (en) 2022-03-03
AU2019403984A1 (en) 2021-06-17
WO2020128447A1 (en) 2020-06-25
CA3121232A1 (en) 2020-06-25
EP3898678A1 (en) 2021-10-27
JP2022513930A (en) 2022-02-09

Similar Documents

Publication Publication Date Title
IL279321A (en) Anti-sirpα antibody
SG11202106214YA (en) Novel anti-ccr8 antibody
IL280780A (en) Anti-tigit antibodies
PT3606954T (en) Anti-lag3 antibodies
IL279352A (en) Il-11ra antibodies
GB201709808D0 (en) Antibodies
IL280013A (en) Anti-il36r antibodies
IL278010A (en) Galectin-10 antibodies
IL289112A (en) Anti-tigit antibodies
GB201707561D0 (en) GARP-TGF-beta antibodies
IL277030A (en) Antibodies
SG11202106171WA (en) Anti-btla antibodies
ZA202101177B (en) Anti-btla antibody
IL291068A (en) Anti-cd73 antibodies
GB201811368D0 (en) Antibody
IL284584A (en) Anti-tigit antibodies
IL281594A (en) Anti-klrg1 antibodies
GB201817172D0 (en) Antibody
GB201905150D0 (en) Ant-ige antibodies
GB201806084D0 (en) Antibodies
GB201917480D0 (en) Antibodies
GB201900732D0 (en) Antibodies
IL289160A (en) Anti-angpt2 antibodies
GB201711785D0 (en) Antibodies
SG11202105718TA (en) Modified antibodies